Abstract
In cystic fibrosis (CF), mutation of the cystic fibrosis transmembrane conductance regulator (CFTR) gene results in defective transepithelial ion transport, leading to life shortening inflammatory lung disease. Before lung studies, we tested the safety and efficacy of gene delivery to the nasal epithelium of CF patients using pCMV-CFTR–DOTAP cationic liposome complex. A single dose of 400 μg pCMV-CFTR:2.4 mg DOTAP was administered in a randomised, double-blinded fashion to the nasal epithelium of eight CF patients, with a further eight receiving buffer only. Patients were monitored for signs and symptoms for 2 weeks before treatment and 4 weeks after treatment. Inflammatory cells were quantified in a nasal biopsy taken 3 days after treatment. There was no evidence for excess nasal inflammation, circulating inflammatory markers or other adverse events ascribable to active treatment. Gene transfer and expression were assayed by the polymerase chain reaction. Transgene DNA was detected in seven of the eight treated patients up to 28 days after treatment and vector derived CFTR mRNA in two of the seven patients at +3 and +7 days. Transepithelial ion transport was assayed before and after treatment by nasal potential difference during drug perfusion and by SPQ fluorescence halide ion conductance. Partial, sustained correction of CFTR-related functional changes toward normal values were detected in two treated patients. The level of gene transfer and functional correction were comparable to those reported previously using adenoviral vectors or another DNA–liposome complex, but here were sustained and uncompromised by false positives. These results justify further studies with pCMV-CFTR–DOTAP aimed at treating CF lung disease.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Porteous, D., Dorin, J., McLachlan, G. et al. Evidence for safety and efficacy of DOTAP cationic liposome mediated CFTR gene transfer to the nasal epithelium of patients with cystic fibrosis. Gene Ther 4, 210–218 (1997). https://doi.org/10.1038/sj.gt.3300390
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/sj.gt.3300390
Keywords
This article is cited by
-
Minicircle DNA Provides Enhanced and Prolonged Transgene Expression Following Airway Gene Transfer
Scientific Reports (2016)
-
Adenoviral Gene Transfer Corrects the Ion Transport Defect in the Sinus Epithelia of a Porcine CF Model
Molecular Therapy (2013)
-
Advances in Cell and Gene-based Therapies for Cystic Fibrosis Lung Disease
Molecular Therapy (2012)
-
Rapid identification of novel functional promoters for gene therapy
Journal of Molecular Medicine (2012)